Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 242)
Posted On: 09/19/2018 5:25:13 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Grows IP Portfolio with Three More Patents in Australia, Two Notices of Allowance in the US
- LXRP receives three new Australian patents and two new notices of allowance from the U.S. patent office; the company expects to receive corresponding patents by year-end 2018
- If issued in both Australia and the U.S., LXRP would then hold 12 issued patents within its first patent family, and it continues to pursue pending application claims in this patent family globally
- The company, which has filed more than 50 patent applications globally, out-licenses its technology that promotes healthier and faster ingestion methods and lower overall dosing
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH (trademarked) ingestion technology platform, is building its strategic intellectual property (IP) portfolio with three more patents in Australia and two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO). LXRP expects to receive corresponding patents in the U.S. prior to year-end 2018 and also expects two more new patents in Australia to be received prior to year-end (http://nnw.fm/E1x1H).
If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new Australian patents are projected to expire on June 10, 2035, it said.
LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform. Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology that has shown faster and more effective delivery of cannabinoids and nicotine. Its IP portfolio already includes a patent for oral delivery of all cannabinoids.
LXRP has now filed a total of more than 50 patent applications across nine current patent families. It is preparing applications for at least seven more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families, it said. It anticipates numerous patents to be granted within each of these families.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- LXRP receives three new Australian patents and two new notices of allowance from the U.S. patent office; the company expects to receive corresponding patents by year-end 2018
- If issued in both Australia and the U.S., LXRP would then hold 12 issued patents within its first patent family, and it continues to pursue pending application claims in this patent family globally
- The company, which has filed more than 50 patent applications globally, out-licenses its technology that promotes healthier and faster ingestion methods and lower overall dosing
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH (trademarked) ingestion technology platform, is building its strategic intellectual property (IP) portfolio with three more patents in Australia and two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO). LXRP expects to receive corresponding patents in the U.S. prior to year-end 2018 and also expects two more new patents in Australia to be received prior to year-end (http://nnw.fm/E1x1H).
If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new Australian patents are projected to expire on June 10, 2035, it said.
LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform. Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology that has shown faster and more effective delivery of cannabinoids and nicotine. Its IP portfolio already includes a patent for oral delivery of all cannabinoids.
LXRP has now filed a total of more than 50 patent applications across nine current patent families. It is preparing applications for at least seven more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families, it said. It anticipates numerous patents to be granted within each of these families.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼